The invention relates to a crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyr- azol-3'-O-.beta.-D-glucopyranoside, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.